Fig. 9

Catumaxomab and aldesleukin have the potential to inhibit sepsis. A The frequency of CD3E⁺ T cells, HLA-DR⁺T cells and IL-2R⁺ T cells in PBMC from patients with sepsis or healthy controls (n = 15). B The proportion of CD4⁺ T cells and CD4⁺ CD25⁺ T cells (gated in CD3E.⁺) after stimulated with catumaxomab (1 μg/ml) and aldesleukin (20 ng/ml) for 24 h (n = 5). IL-10 (C), IL-1β, TNF-α and IL-6 (D) expression level were measured by QPCR (n = 5)